Teva (TEVA) Ends Dispute with Amgen Over Generic Sensipar

Teva Pharmaceutical IndustriesLtd.TEVA announced settlement of an ongoing patent dispute with biotech giant, Amgen, Inc. AMGN related to its generic version of Amgen's secondary hyperparathyroidism product, Sensipar (cinacalcet HCl).

Sensipar lost patent exclusivity in March last year and Teva recently launched its generic version, at-risk.

The settlement will end the patent dispute between the two companies and the Israel-based drugmaker will make an undisclosed payment to Amgen. Teva will no longer sell its generic product until its license date in mid-year 2021. Other terms of the settlement remain undisclosed.

Shares of Teva have declined 19% in the past year compared with the industry 's decline of 27.8%.

Teva has been active in settling patent issues, which has contributed to its growth. Challenging patents continues to be an important part of its generic product selection and development strategy.

Active patent challenges require litigation, thereby leading to higher general and administration expenses. Therefore, the settlement of these challenges accelerates the availability of low cost generic products and also removes uncertainties associated with litigation.

Teva currently carries a Zacks Rank #3 (Hold).You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Some better-ranked generic drugmakers are Bausch Health Cos Inc. BHC and Dr. Reddy's Laboratories RDY . While Bausch Health has a Zacks Rank #1 (Strong Buy), Dr. Reddy's has a Zacks Rank #2 (Buy).

For Bausch, earnings estimates have moved up 5.8% for 2019 in the past 60 days. The company surpassed earnings estimates in three of the past four quarters with the average beat being 83.24%.

Shares of Dr. Reddy's have risen 14.9% in the past six months. The Zacks Consensus Estimate for earnings has increased 2.4% for 2019 in the past 60 days.

More Stock News: This Is Bigger than the iPhone !

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Amgen Inc. (AMGN): Free Stock Analysis Report

Dr. Reddy's Laboratories Ltd (RDY): Free Stock Analysis Report

Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report

Bausch Health Cos Inc. (BHC): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.